| Name | Title | Contact Details |
|---|---|---|
Alex Driggs |
General Counsel and Corporate Secretary | Profile |
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
Nulixir is a B2B nanobiotechnology company that develops, manufactures, and licenses intellectual property for smart nanocarriers, called nanovesicles, which optimize the performance of functional ingredients in food & beverage products.
QoL Meds is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cancer cell surface. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.